Purpose Tacrolimus (TAC) is used for the prophylaxis and treatment of acute graft-versus-host disease after bone marrow transplantation (BMT). However, few have reported on TAC-induced left ventricular hypertrophy. This study aimed to assess the relationship between blood concentration of TAC and development of TAC-induced left ventricular (TI-LV) dysfunction in adult BMT patients with hematologic malignant diseases, and to evaluate whether TAC concentration can predict TI-LV dysfunction occurrence in these patients. Methods We enrolled 16 consecutive patients (mean age 44.6 ± 13.0 years) who received TAC after BMT. Echocardiography was performed before and after BMT, and blood concentrations of TAC were evaluated in terms of AUC 15 (area sum of TAC > 15 ng/ml during follow-up). We assessed the relationship between AUC 15 and development of TI-LV dysfunction after TAC. Results During the follow-up period (mean duration 47.6 ± 13.7 days), interventricular septum thickness (IVST, P = 0.001) and posterior wall thickness (PWT, P < 0.001) increased, and E′ decreased (P = 0.006). AUC 15 was associated with post-IVST (R = 0.627, P = 0.009), post-PWT (R = 0.669, P = 0.005), and post-E′ (R = − 0.767, P = 0.001). In multivariate analysis, AUC 15 and age independently predicted the increase in IVST and PWT and decrease in E′ after BMT. The combination of AUC 15 and older age predicted post-PWT with a sensitivity of 77.8% and specificity of 71.4%. Conclusion TAC concentrations should be maintained at < 15 ng/ml and age should be considered in patients undergoing BMT to avoid TI-LV dysfunction.
Introduction
Tacrolimus (TAC) has been used for the prophylaxis and treatment of graft rejection after solid organ transplantation and acute graft-versus-host disease (GVHD) after bone marrow transplantation (BMT) [1] [2] [3] [4] [5] . Given the narrow therapeutic range of TAC, studies have shown that blood concentrations of TAC should be kept in the range of 10-20 ng/ml to prevent adverse effects such as nephrotoxicity or neurotoxicity [2, 6] . Previous studies have also reported development of TAC-induced myocardial hypertrophy after TAC administration [7] [8] [9] [10] [11] [12] [13] [14] . According to one study, a high concentration of TAC (i.e., > 15 ng/ml) predicted the subsequent risk of developing myocardial hypertrophy [15] . However, that study was based on measurement of TAC concentration at a single time point, in which TAC was considered to be the cause of left ventricular hypertrophy (LVH). Thus, it is unclear whether sustained high concentrations of TAC are related to the development of LVH. While some reports have touched on the relationship between the blood concentration of TAC and LVH, there are no diagnostic criteria for TI-LV dysfunction, and thus no report has investigated the changes in cardiac function in detail observed by echocardiology. Moreover, no studies have reported on factors that can predict TI-LV dysfunction after BMT.
This study aimed to assess the relationship between blood concentration of TAC and development of TI-LV dysfunction in adult BMT patients with hematologic malignant diseases, and to evaluate whether blood concentration of TAC can predict TI-LV dysfunction in these patients.
Materials and methods

Patient population and study protocol
This was a single-center retrospective cohort study. We enrolled 16 consecutive patients (10 men, mean age 44.6 ± 13.0 years) who underwent BMT from unrelated donors for myelodysplastic syndrome, acute lymphoid leukemia, acute/chronic myelogenous leukemia, or malignant lymphoma at Ohta Nishinouchi Hospital between January 2016 and May 2017 ( Table 1) . Exclusion criteria included a previous history of cardiovascular disease, left ventricular systolic dysfunction [LV ejection fraction (LVEF) < 50%], and age < 20 years.
All patients received chemotherapy including cardiotoxic agents before BMT (Table 1) and underwent BMT at first remission, second remission, or at untreated first relapse. After BMT, patients received TAC as immunosuppressive therapy. Blood concentrations of TAC were monitored in all patients during the study period.
Echocardiography was performed before BMT (as baseline) and after TAC (at 1-2 months after BMT when patients were able to leave the clean room) ( Fig. 1 ). We assessed relationships between TAC concentration and the echocardiographic index of systolic/diastolic function post-BMT and also investigated whether TI-LV dysfunction could be predicted based on TAC concentration, patient characteristics, and/or echocardiographic findings at baseline in multivariate analyses.
Immunosuppressive therapy and measurement of TAC blood concentration
All patients received preparative regimens and were scheduled to continue immunosuppression with TAC, which was given by continuous infusion between the day before BMT and successful engraftment (30-40 days). Target blood concentrations of TAC ranged from 10 to 30 ng/ml. Blood concentration of TAC was measured every few days, and the dose was adjusted by the hematologist during the treatment course. 
Analysis of TAC concentration
Whole blood samples were extracted with methylene chloride and assayed for TAC concentration by chemiluminescent immunoassays (Abbott, Chicago, IL). Whole blood concentration of TAC vs days after BMT was plotted ( Fig. 1 ). High concentrations of TAC, in particular, TAC > 15 ng/ml, reportedly pose a risk of developing LVH [15] . Thus, we defined the parameters of TAC concentration between the day of BMT and follow-up echocardiography as follows: C mean (ng/ml), mean concentration of TAC; AUC Total (ng/ ml day), area under the blood concentration-time curve using the linear trapezoidal rule; and AUC 15 (ng/ml day), area sum of TAC concentrations > 15 ng/ml during the follow-up period.
Echocardiography
Echocardiography was performed in the left lateral decubitus position using the Vivid E95 (GE Healthcare, Milwaukee, WI) or iE33 (Philips Healthcare, Andover, MA) at baseline and after TAC. All measurements were performed by the author (KK, intra-observer variability: 95% ICC 0.83-0.91, CV 2.6-3.1%) and confirmed by the co-author (MIT), who is an echocardiography specialist. Standard two-dimensional echocardiography was performed according to the recommendations of the American Society of Echocardiography [16] . LV internal dimensions and wall thickness were measured in the parasternal longaxis view. LV mass and mass index were calculated with the cube formula. LVEF was calculated using a modified version of Simpson's method. LV diastolic functional parameters including peak early filling (E velocity) and late filling (A velocity) were assessed using pulsed-wave Doppler images, and peak systolic velocity (S′), peak early diastolic velocity (E′), and peak late diastolic velocity (A′) were assessed using tissue Doppler images. E/E′ ratio was also determined [17] .
In 12 patients, global longitudinal strain (GLS) was evaluated in apical four-, two-, and three-chamber views with a high frame rate (> 50 frames/s) using off-line software (Echo PAC v201 TM , GE Healthcare). It was impossible to calculate GLS in four patients due to poor imaging. By tracing the endocardial borders on an end-systolic frame, myocardial speckles were automatically tracked on subsequent frames. Adequate tracking was verified and manually corrected if necessary. Finally, the average of GLS from three different views was calculated.
Statistical analysis
Statistical analyses were performed using SPSS™ software version 23.0 (IBM, New York, USA). Data are expressed as n (%) or mean ± standard deviation. Differences in echocardiographic measurements between baseline and followup were analyzed using paired Student's t tests. Pearson's product moment coefficient and linear regression were used to compare TAC concentration and echocardiographic measurements. P < 0.05 was considered statistically significant (two-sided). In addition, receiver operating characteristic (ROC) curve analysis and multivariate analyses were performed to identify factors that could predict the occurrence of TI-LV dysfunction. Confounding variables were those found to be significant in the univariate analysis.
Results
Patient characteristics
Among the 16 patients in this study, only 1 (6.3%) had a medical history of hypertension. None of the other patients had cardiovascular-related symptoms or cardiovascular risk factors such as diabetes, dyslipidemia, obesity, or chronic kidney disease prior to BMT (Table 1 ).
Immunosuppressive therapy after BMT and TAC concentration
During the follow-up period, 2 of 16 patients (12.5%) presented with GVHD despite immunosuppressive therapy with TAC. TAC concentration indices were as follows ( Table 1) : C mean 14.5 ± 3.2 ng/ml, AUC Total 677.8 ± 176.7 (ng/ml day), and AUC 15 97.1 ± 51.6 (ng/ml day). All patients had a certain time period where TAC blood concentration was higher than 15 ng/ml. 
Changes in hemodynamic and echocardiographic parameters between baseline and after TAC
We also performed echocardiography at baseline and after TAC. The follow-up period was 47.6 ± 13.7 days (range 32-74 days). Hemodynamic and echocardiographic parameters are shown in Table 2 . At baseline, there were no significant abnormal findings, such as hypertension, bradycardia or tachycardia, renal failure, LVH, dilatation of cardiac chambers, LV systolic and diastolic dysfunction, and valvular heart disease.
LVH significantly increased from baseline to after TAC [interventricular septum thickness (IVST): 8.7 ± 1.2 to 9.9 ± 1.7 mm, P = 0.001; posterior wall thickness (PWT): 9.0 ± 1.1 to 10.4 ± 1.3 mm, P < 0.001]. LV end-diastolic diameter also significantly decreased from 46.6 ± 4.0 to 41.5 ± 7.5 mm (P = 0.006). However, there were no changes in LV end-systolic diameter, LVEF, LV mass, and LV mass index during the follow-up period. No significant differences were seen in hemodynamic parameters between baseline and after TAC.
Mitral inflow decreased in E velocity (75.4 ± 22.0 to 62.4 ± 20.5 cm/s, P = 0.047) and E/A (1.2 ± 0.3 to 1.0 ± 0.3, P = 0.035). E′ also decreased from 8.8 ± 2.2 cm/s to 6.8 ± 1.6 cm/s (P = 0.006), but E/E′ did not change significantly.
GLS was slightly reduced at baseline despite the preserved LVEF and showed a tendency to decline after TAC (− 18.3 ± 3.6 to − 15.4 ± 4.3%, P = 0.062).
Clinical presentation
Two of 16 patients (12.5%) developed symptomatic heart failure during the follow-up period. Echocardiographic changes in a 31-year-old female who developed heart failure after TAC are shown in Fig. 2 . She received BMT due to acute lymphoid leukemia and developed rapid progression of concentric hypertrophy and a narrowing of the LV cavity after TAC (Fig. 2, a-1 , a-2, b-1, b-2). The mitral inflow pattern changed from a normal pattern to an abnormal relaxation pattern (Fig. 2, a-3, b-3 ). E′ decreased from 10.8 to 4.2 cm/s (Fig. 2, a-4, b-4) , and E/E′ increased from 9.0 to 14.9. She presented with GVHD and therefore was given a higher dose of TAC [C mean : 16.2 ng/ml, AUC Total : 1198.6 (ng/ml day), AUC 15 : 178.9 (ng/ml day)]. As these serial changes suggested TI-LV dysfunction, the TAC dose was reduced to lower the blood concentration < 15 ng/ml. After 7 days at the lower dose, IVST decreased from 10.8 to 9.6 mm, E/E′ decreased from 14.9 to 11.8, and E′ increased from 4.2 to 6.4 cm/s.
Relationship between echocardiography and TAC concentration
We next assessed the relationships between TAC concentration and hemodynamic and echocardiographic parameters. At baseline, TAC concentration was not associated with hemodynamic and echocardiographic parameters. Moreover, hemodynamic parameters were not associated with TAC concentration and echocardiographic parameters.
After TAC, AUC Total was associated with strain (R = 0.572, P = 0.021) and E′ (R = − 0.641, P = 0.007). Moreover, AUC 15 was strongly correlated with post-IVST (R = 0.627, P = 0.009), post-PWT (R = 0.669, P = 0.005), and post-E′ (R = − 0.767, P = 0.001) ( Fig. 3) . However, C mean was not correlated with echocardiographic parameters.
In univariate analysis, post-IVST was associated with age, eGFR, and AUC 15 , and post-PWT was associated with AUC 15 and tended to correlate with age. Indices that were significant in univariate analysis (P < 0.05) were evaluated in multivariate analysis. In multivariate analysis, age and AUC 15 were independent predictors of post-IVST and post-PWT (Table 3) . Pre-IVST and pre-E′ correlated with age (pre-IVST: R = 0.516, P = 0.04) (pre-E′: R = -0.542, P = 0.03); however, post-IVST, post-PWT, and post-E′ remained correlated with AUC 15 after adjusting for age. ROC curve analyses for predicting the increase in PWT (≥ 1 mm) were as follows: by AUC 15 (AUC: 0.698, cutoff value: 89.6 ng/ml, sensitivity: 66.7%, and specificity: 71.4%), by age (AUC: 0.516, cutoff value: 42.5 years old, sensitivity: 66.7%, and specificity: 57.1%), and by AUC 15 + age (y = 6.9 77 + 0.045 × age + 0.016 × AUC 15 , cutoff value: 10.5, AUC: 0.714, sensitivity: 77.8%, and specificity: 71.4%) ( Fig. 4 ).
Discussion
In this study, we assessed the relationship between blood concentration of TAC and development of TI-LV dysfunction, and also evaluated whether the occurrence of TI-LV dysfunction could be predicted in adult BMT patients with hematologic malignant diseases. Our major findings were as follows: (1) there were clear dose-response relationships between indices of TAC concentration and TI-LV dysfunction; (2) a combination of older age and AUC 15 predicted TI-LV dysfunction; and (3) TI-LV dysfunction affects not only the increase in LV wall thickness, but also provokes LV diastolic dysfunction. To the best of our knowledge, TAC, which is also known as the macrolide antibiotic FK506, is classified as a calcineurin inhibitor and is a potent immunosuppressive agent used for the prevention of acute GVHD after solid organ transplant and BMT. TAC binds to FK506-binding protein (FKBP) and the complex inhibits calcineurin, thereby preventing T cell activation [18, 19] . Several adverse effects of high concentrations of TAC have been reported, including nephrotoxicity, neurotoxicity, diarrhea, other gastrointestinal disturbances, increased risk of infection, hypertension, and disturbances in glucose metabolism [5] . Therefore, to prevent nephrotoxicity, the target therapeutic range of TAC is 10-20 ng/ml [2, 6] .
Atkinson et al. first reported hypertrophic cardiomyopathy induced by TAC in pediatric recipients of small bowel or liver transplants [7] . Higher concentrations of TAC are associated with acute myocardial hypertrophy. According to a study by Nakata et al., a TAC concentration > 15 ng/ml is associated with an increased risk of LVH after liver transplantation [15] . However, there are no diagnostic criteria for TI-LV dysfunction, and no studies on LV diastolic dysfunction caused by TAC have been published. Dose-response relationships between TAC and TI-LV dysfunction have also been unclear.
Consistent with previous reports [7] [8] [9] [10] [11] [12] [13] [14] [15] , increased LV wall thickness and concentric remodeling were apparent in our patients after TAC administration. LV diastolic dysfunction was also observed, as reflected in the decreases in E velocity, E/A, and E′. Furthermore, there were clear dose-response relationships between AUC 15 and echocardiographic findings, i.e., the increase in IVST and PWT and decrease in E′. TI-LV dysfunction should be defined not only by wall thickness, but also by development of diastolic dysfunction. We performed a preliminary study to investigate the optimal blood concentration of TAC (10, 12.5, 15, 17.5, 20 ng/ml) to prevent TI-LV dysfunction, which indicated that blood concentrations of TAC should be kept under 15 ng/ml. Although the pathogenesis of TI-LV dysfunction is still unclear, a number of mechanisms by which the effects FKBP on the myocardium can lead to cardiac hypertrophy have been reported. FKBP stabilizes the ryanodine receptor, which modulates calcium release in the sarcoplasmic reticulum of the myocardium. The binding of TAC to FKBP releases FKBP from the ryanodine receptor, resulting in altered intracellular calcium signaling that can lead to cardiac hypertrophy [18] [19] [20] [21] . Chronic treatment with TAC has also been reported to inhibit nitric oxide synthesis, leading to activation of 70-kD S6 kinase, which plays an important role in cardiac hypertrophy by regulating protein synthesis [22, 23] .
In general, the prevalence of LV diastolic dysfunction increases with age [17] . Although our study population included young and middle-aged adults, we found that a combination of age and AUC 15 predicted TI-LV dysfunction in adult patients after TAC. Previous reports focused on pediatric transplant cases, and thus the impact of age was not considered. Our present findings suggest that age is an important factor when evaluating LV diastolic dysfunction and monitoring AUC 15 , particularly in adult patients after TAC.
Some have reported that LVH is reversible and can improve after discontinuing TAC [24] [25] [26] . There are also some reports denying that tacrolimus-induced LV hypertrophy actually exists [27, 28] . However, these reports did not evaluate LV diastolic function, and thus may have failed to detect TI-LV dysfunction due to missing the timing for echocardiography. In our study population, there was an increase in LV wall thickness and LV diastolic dysfunction even in the absence of LVH.
In our study population, symptomatic heart failure occurred in two patients. Moreover, LV diastolic dysfunction appeared in accordance with TAC concentration. We also experienced cases in which an increase in LV wall thickness persisted for several months after withdrawing TAC in spite of improvement in LV chamber narrowing. This suggests that the increase in myocardial wall thickness was due to myocardial injury caused by TAC, rather than Laplace's law. The presence of diastolic dysfunction reportedly predicts development of heart failure and confers a higher risk of mortality [17] . Development of heart failure will exacerbate the patient's condition after BMT. Thus, we believe it is essential to predict TI-LV dysfunction in patients who receive TAC, and that the use of TAC should be balanced with the risk of developing TI-LV dysfunction.
Study limitations
There were several limitations in this study. First, this was a retrospective single-center study involving a small sample size. Therefore, our findings will need to be confirmed in studies with a larger sample size. Second, we could not detect the timing when TI-LV dysfunction appeared during TAC administration because we performed echocardiography only once after induction of TAC. Thus, we were unable to assess serial changes in echocardiographic parameters. Third, we focused on TAC-related changes, and thus relationships between other immunosuppressive agents and cardiac function remain unclear. Fourth, we did not perform biopsy of the myocardium, so we were unable to identify the histological changes in the myocardium induced by TAC. Fifth, we could not exclude the influence of radiology and chemotherapy with various cardiotoxic agents that the patients underwent prior to the study period. In fact, the decrease in GLS, which reflected potential systolic dysfunction, was observed at baseline in some patients despite preserved LVEF. The results in these patients may have been influenced by chemotherapy with cardiotoxic agents. Finally, we did not assess BNP as a marker of heart failure.
Conclusion
Our study revealed that AUC 15 and older age were associated with TI-LV dysfunction, and that TI-LV dysfunction may be more prevalent in adult patients treated with TAC after BMT. This highlights the importance of evaluating TAC concentration and the age of patients who undergo BMT when considering the possibility of developing TI-LV dysfunction, as well as the need to carefully focus on diastolic function during follow-up echocardiography.
